EW Overview

Edwards Lifesciences Corporation is a global structural heart company. Its work includes both surgical and transcatheter therapies. Its portfolio of repair and replacement technologies for aortic, mitral, tricuspid and pulmonic heart valves provides a set of treatment options to serve the diverse and complex patients in need. Its product categories include Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies (TMTT), and Surgical. It provides transcatheter heart valve replacement technologies designed for the minimally invasive replacement of aortic heart valves. Its products include SAPIEN 3 Ultra RESILIA transcatheter heart valve, SAPIEN 3 Ultra transcatheter heart valve, SAPIEN 3 transcatheter heart valve and Alterra adaptive prestent. TMTT category includes PASCAL transcatheter repair system, EVOQUE tricuspid valve replacement system and SAPIEN M3 mitral valve replacement system. INSPIRIS RESILIA aortic valve offers RESILIA tissue and VFit technology.

Wall Street analysts forecast EW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EW is96.52 USD with a low forecast of 84.00 USD and a high forecast of 105.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Edwards Lifesciences Corp revenue for the last quarter amounts to 1.65B USD, increased 16.70

Edwards Lifesciences Corp. EPS for the last quarter amounts to 0.66 USD, increased 8.20

Edwards Lifesciences Corp (EW) has 16000 emplpoyees as of July 07 2026.

Today EW has the market capitalization of 54.60B USD.